Dr. Adam L. Cohen

Oral and Maxillofacial Surgery
21 E Main St, 
Moorestown, NJ 
 (936.9 mi)
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
21 E Main St, 
Moorestown, NJ 
 (936.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

Adam Cohen is an Oral and Maxillofacial Surgeon in Moorestown, New Jersey. His top areas of expertise are Mouth Sores and Mouth Ulcers. Dr. Cohen is currently accepting new patients.

His clinical research consists of co-authoring 58 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oral and Maxillofacial Surgery
Licenses
Dentist in PA
Languages Spoken
English
Arabic
Farsi
French
German
Italian
Japanese
Mandarin
Russian
Spanish
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Florida Combined Life
  •  Anthem
  •  BEST
  •  UnitedHealthcare

Locations

21 E Main St, Moorestown, NJ 08057

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Enrollment Status: Recruiting
Publish Date: February 20, 2025
Intervention Type: Procedure, Biological, Radiation
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Enrollment Status: Suspended
Publish Date: February 25, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Other, Drug
Study Drugs: Vemurafenib, Cobimetinib
Study Phase: Phase 2
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition
Enrollment Status: Terminated
Publish Date: October 03, 2024
Intervention Type: Drug
Study Drug: Drug determined by treating oncologist based on recommendation from systems biology analysis
Study Phase: Phase 2
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: August 02, 2024
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
A Phase 2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001
Enrollment Status: Active_not_recruiting
Publish Date: June 28, 2024
Intervention Type: Drug, Radiation
Study Drugs: BMX-001, Temozolomide
Study Phase: Phase 2
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug, Other, Biological
Study Drugs: Enobosarm, Pembrolizumab
Study Phase: Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)
Enrollment Status: Completed
Publish Date: May 11, 2023
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Depatuxizumab
Study Phase: Phase 3
A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Biological
Study Drug: CAR2 Anti-CD38 A2 CAR-T Cells
Study Phase: Phase 1
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2021
Intervention Type: Drug, Procedure
Study Drugs: Carmustine, Cytarabine, Etoposide, Thiotepa, Granulocyte Colony-Stimulating Factor
Study Phase: Phase 2
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer
An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer
Enrollment Status: Terminated
Publish Date: January 08, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Study to Identify Predictors of Response to Duloxetine in Breast Cancer Patients With Chronic Pain
A Study to Identify Predictors of Response to Duloxetine in Breast Cancer Patients With Chronic Pain
Enrollment Status: Completed
Publish Date: August 06, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: September 18, 2019
Intervention Type: Drug
Study Phase: Phase 1
Phase 1 Trial in Newly Diagnosed High Grade Glioma With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide. (D-TERMINED)
Phase 1 Trial in Newly Diagnosed High Grade Glioma With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide. (D-TERMINED)
Enrollment Status: Completed
Publish Date: June 19, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)
Enrollment Status: Terminated
Publish Date: March 26, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 18 Less Clinical Trials

58 Total Publications

Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Journal: Neuro-oncology advances
Published: December 30, 2024
Similar Doctors
Expertise in
12
conditions
Dr. Thomas P. Sollecito
Oral and Maxillofacial Surgery | General Surgery
Expertise in
12
conditions
Dr. Thomas P. Sollecito
Oral and Maxillofacial Surgery | General Surgery

University Of Penn - Medical Group

3400 Spruce Street 5 White Bldg, Oral And Maxillofacial Surgery Hup, 
Philadelphia, PA 
 (13.4 mi)
215-829-6079
Languages Spoken:
English
See accepted insurances

Thomas Sollecito is an Oral and Maxillofacial Surgeon and a General Surgeon in Philadelphia, Pennsylvania. Dr. Sollecito is highly rated in 12 conditions, according to our data. His top areas of expertise are Leukoplakia, Mouth Sores, Mouth Ulcers, TMJ Disorders, and Microvascular Decompression.

Expertise in
23
conditions
Dr. Rabie M. Shanti
Oral and Maxillofacial Surgery | General Surgery | Otolaryngology
Expertise in
23
conditions
Dr. Rabie M. Shanti
Oral and Maxillofacial Surgery | General Surgery | Otolaryngology

Rutgers University Dental Associates-New Brunswick

135 Somerset St, Suite A, 
New Brunswick, NJ 
 (45.2 mi)
732-235-5050
Experience:
14+ years
Languages Spoken:
English, Arabic, Castilian, French, Hebrew, Hindi, Korean, Mandarin, Portuguese, Russian, Spanish, Vietnamese
See accepted insurances
Accepting New Patients

Rabie Shanti is an Oral and Maxillofacial Surgeon and a General Surgeon in New Brunswick, New Jersey. Dr. Shanti has been practicing medicine for over 14 years is highly rated in 23 conditions, according to our data. His top areas of expertise are Oral Cancer, Leukoplakia, Mouth Ulcers, Osteotomy, and Gastrostomy. Dr. Shanti is currently accepting new patients.

Expertise in
7
conditions
Dr. Robert J. Diecidue
Oral and Maxillofacial Surgery | General Surgery
Expertise in
7
conditions
Dr. Robert J. Diecidue
Oral and Maxillofacial Surgery | General Surgery

Jefferson University Physicians

111 S 11th St, 
Philadelphia, PA 
 (11.3 mi)
Languages Spoken:
English, Arabic, Bosnian, Farsi, Filipino, Mandarin, Spanish
See accepted insurances
Accepting New Patients

Robert Diecidue is an Oral and Maxillofacial Surgeon and a General Surgeon in Philadelphia, Pennsylvania. Dr. Diecidue is highly rated in 7 conditions, according to our data. His top areas of expertise are Ludwig Angina, Uvulitis, Mouth Sores, and Mouth Ulcers. Dr. Diecidue is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile